Home/Pipeline/AUM302 (formerly IBL-302)

AUM302 (formerly IBL-302)

Cancer

Pre-clinical (partnered)Active

Key Facts

Indication

Cancer

Phase

Pre-clinical (partnered)

Status

Active

Company

Inflection Biosciences

About Inflection Biosciences

Inflection Biosciences is a private, pre-revenue biotech developing novel dual PIM/PI3K kinase inhibitors for oncology and inflammatory diseases. Its lead asset, IBL-202, is in pre-clinical development for aggressive B-cell malignancies and T-cell lymphoma, while AUM302 (IBL-302) is partnered with AUM Biosciences. The company leverages a network of academic collaborations, including a foundational license from the Spanish National Cancer Research Centre (CNIO), and has secured non-dilutive funding from the EU's Horizon 2020 program.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases Inflammatory Diseases

Other Cancer Drugs

Drug	Company	Phase	Status
Not Specified (Oncology Focus)	Narwhal Bio	Pre-clinical	Active
EDM Platform for Genetic Medicine	Coastar Therapeutics	Pre-clinical	Platform Development
CO-1	Caedo Oncology	Pre-clinical	Active R&D
Anti-CD99 monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Anti-HLA class I monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Triapine®	Nanopharmaceutics	Clinical	Active
Ammonium Tetrathiomolybdate	Nanopharmaceutics	Clinical	Active
Aza-TdC	Nanopharmaceutics	Clinical	Active
Undisclosed Oncology Program(s)	Cell BioEngines	Phase 1	Active
No-alpha IL-2 Mutein	SarcoMed USA	Pre-clinical	Active
PMIS Therapeutic	NaturemiRI	Preclinical/Clinical (unspecified)	Active
Undisclosed DDR Sensor Program(s)	NERx Biosciences	Pre-clinical	Active